Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Thyroid Cancer | Research

A nomogram for predicting adverse pathologic features in low-risk papillary thyroid microcarcinoma

Authors: Lei Gong, Ping Li, Jingjing Liu, Yan Liu, Xinghong Guo, Weili Liang, Bin Lv, Peng Su, Kai Liang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Identifying risk factors for adverse pathologic features in low-risk papillary thyroid microcarcinoma (PTMC) can provide valuable insights into the necessity of surgical or non-surgical treatment. This study aims to develop a nomogram for predicting the probability of adverse pathologic features in low-risk PTMC patients.

Methods

A total of 662 patients with low-risk PTMC who underwent thyroid surgery were retrospectively analyzed in Qilu Hospital of Shandong University from May 2019 to December 2021. Logistic regression analysis was used to determine the risk factors for adverse pathologic features, and a nomogram was constructed based on these factors.

Results

Most PTMC patients with these adverse pathologic features had tumor diameters greater than 0.6 cm (p < 0.05). Other factors (age, gender, family history of thyroid cancer, history of autoimmune thyroiditis, and BRAFV600E mutation) had no significant correlation with adverse pathologic features (p > 0.05 each). The nomogram was drawn to provide a quantitative and convenient tool for predicting the risk of adverse pathologic features based on age, gender, family history of thyroid cancer, autoimmune thyroiditis, tumor size, and BRAFV600E mutation in low-risk PTMC patients. The areas under curves (AUC) were 0.645 (95% CI 0.580–0.702). Additionally, decision curve analysis (DCA) and calibration curves were used to evaluate the clinical benefits of this nomogram, presenting a high net benefit.

Conclusion

Tumor size > 0.60 cm was identified as an independent risk factor for adverse pathologic features in low-risk PTMC patients. The nomogram had a high predictive value and consistency based on these factors.
Literature
1.
go back to reference Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, Vaccarella S. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264–72.CrossRefPubMed Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, Vaccarella S. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264–72.CrossRefPubMed
2.
go back to reference Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.CrossRefPubMed Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.CrossRefPubMed
3.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
4.
go back to reference Orloff LA, Noel JE, Stack BC Jr, Russell MD, Angelos P, Baek JH, Brumund KT, Chiang FY, Cunnane MB, Davies L, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. Head Neck. 2022;44(3):633–60.CrossRefPubMed Orloff LA, Noel JE, Stack BC Jr, Russell MD, Angelos P, Baek JH, Brumund KT, Chiang FY, Cunnane MB, Davies L, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. Head Neck. 2022;44(3):633–60.CrossRefPubMed
5.
go back to reference Koot A, Soares P, Robenshtok E, Locati LD, de la Fouchardiere C, Luster M, Bongiovanni M, Hermens R, Ottevanger P, Geenen F, et al. Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma. Eur J Cancer. 2023;179:98–112.CrossRefPubMed Koot A, Soares P, Robenshtok E, Locati LD, de la Fouchardiere C, Luster M, Bongiovanni M, Hermens R, Ottevanger P, Geenen F, et al. Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma. Eur J Cancer. 2023;179:98–112.CrossRefPubMed
6.
go back to reference Sasaki T, Miyauchi A, Fujishima M, Ito Y, Kudo T, Noda T, Sano T, Kishi T, Nakamura T. Comparison of Postoperative Unfavorable Events in Patients with Low-Risk Papillary Thyroid Carcinoma: Immediate Surgery Versus Conversion Surgery Following Active Surveillance. Thyroid. 2023;33(2):186–91.CrossRefPubMedPubMedCentral Sasaki T, Miyauchi A, Fujishima M, Ito Y, Kudo T, Noda T, Sano T, Kishi T, Nakamura T. Comparison of Postoperative Unfavorable Events in Patients with Low-Risk Papillary Thyroid Carcinoma: Immediate Surgery Versus Conversion Surgery Following Active Surveillance. Thyroid. 2023;33(2):186–91.CrossRefPubMedPubMedCentral
7.
go back to reference Chou R, Dana T, Haymart M, Leung AM, Tufano RP, Sosa JA, Ringel MD. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review. Thyroid. 2022;32(4):351–67.CrossRefPubMed Chou R, Dana T, Haymart M, Leung AM, Tufano RP, Sosa JA, Ringel MD. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review. Thyroid. 2022;32(4):351–67.CrossRefPubMed
8.
go back to reference Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13(4):381–7.CrossRefPubMed Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13(4):381–7.CrossRefPubMed
9.
go back to reference Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, Shindo H, Teshima M, Horiguchi K, Yoshida Y, Kanai T, et al. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery Task Force on management for papillary thyroid microcarcinoma. Thyroid. 2021;31(2):183–92.CrossRefPubMedPubMedCentral Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, Shindo H, Teshima M, Horiguchi K, Yoshida Y, Kanai T, et al. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery Task Force on management for papillary thyroid microcarcinoma. Thyroid. 2021;31(2):183–92.CrossRefPubMedPubMedCentral
10.
go back to reference Pitt SC, Saucke MC, Roman BR, Alexander SC, Voils CI. The influence of emotions on treatment decisions about low-risk thyroid cancer: a qualitative study. Thyroid. 2021;31(12):1800–7.CrossRefPubMedPubMedCentral Pitt SC, Saucke MC, Roman BR, Alexander SC, Voils CI. The influence of emotions on treatment decisions about low-risk thyroid cancer: a qualitative study. Thyroid. 2021;31(12):1800–7.CrossRefPubMedPubMedCentral
11.
go back to reference Chung SR, Baek JH, Choi YJ, Lee JH. Thermal ablation for the management of papillary thyroid microcarcinoma in the era of active surveillance and hemithyroidectomy. Curr Oncol Rep. 2022;24(8):1045–52.CrossRefPubMed Chung SR, Baek JH, Choi YJ, Lee JH. Thermal ablation for the management of papillary thyroid microcarcinoma in the era of active surveillance and hemithyroidectomy. Curr Oncol Rep. 2022;24(8):1045–52.CrossRefPubMed
12.
go back to reference Van Dijk SPJ, Coerts HI, Gunput STG, van Velsen EFS, Medici M, Moelker A, Peeters RP, Verhoef C, van Ginhoven TM. Assessment of radiofrequency ablation for papillary microcarcinoma of the thyroid: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2022;148(4):317–25.CrossRefPubMedPubMedCentral Van Dijk SPJ, Coerts HI, Gunput STG, van Velsen EFS, Medici M, Moelker A, Peeters RP, Verhoef C, van Ginhoven TM. Assessment of radiofrequency ablation for papillary microcarcinoma of the thyroid: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2022;148(4):317–25.CrossRefPubMedPubMedCentral
13.
go back to reference Hwang H, Choi JY, Yu HW, Moon JH, Kim JH, Lee EK, Kim YK, Lee CY, Cho SW, Chung EJ, et al. Surgical outcomes in patients with low-risk papillary thyroid microcarcinoma from maestro study: immediate operation versus delayed operation after active surveillancea multicenter prospective cohort study. Ann Surg. 2023;278(5):e1087–95.CrossRefPubMed Hwang H, Choi JY, Yu HW, Moon JH, Kim JH, Lee EK, Kim YK, Lee CY, Cho SW, Chung EJ, et al. Surgical outcomes in patients with low-risk papillary thyroid microcarcinoma from maestro study: immediate operation versus delayed operation after active surveillancea multicenter prospective cohort study. Ann Surg. 2023;278(5):e1087–95.CrossRefPubMed
14.
go back to reference Han ZY, Dou JP, Zheng L, Che Y, Yu MA, Wang SR, Wang H, Cong ZB, He JF, Qian TG, et al. Safety and efficacy of microwave ablation for the treatment of low-risk papillary thyroid microcarcinoma: a prospective multicenter study. Eur Radiol. 2023;33(11):7942–51.CrossRefPubMed Han ZY, Dou JP, Zheng L, Che Y, Yu MA, Wang SR, Wang H, Cong ZB, He JF, Qian TG, et al. Safety and efficacy of microwave ablation for the treatment of low-risk papillary thyroid microcarcinoma: a prospective multicenter study. Eur Radiol. 2023;33(11):7942–51.CrossRefPubMed
15.
go back to reference Al-Qurayshi Z, Nilubol N, Tufano RP, Kandil E. Wolf in sheep’s clothing: papillary thyroid microcarcinoma in the US. J Am Coll Surg. 2020;230(4):484–91.CrossRefPubMedPubMedCentral Al-Qurayshi Z, Nilubol N, Tufano RP, Kandil E. Wolf in sheep’s clothing: papillary thyroid microcarcinoma in the US. J Am Coll Surg. 2020;230(4):484–91.CrossRefPubMedPubMedCentral
16.
go back to reference Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341–6.CrossRefPubMed Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341–6.CrossRefPubMed
17.
go back to reference Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.CrossRefPubMedPubMedCentral Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.CrossRefPubMedPubMedCentral
18.
go back to reference Wilhelm A, Conroy PC, Calthorpe L, Shui AM, Kitahara CM, Roman SA, Sosa JA. Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid Cancer and Distant Metastases in the United States, 1992–2018. Thyroid. 2023;33(1):63–73.CrossRefPubMedPubMedCentral Wilhelm A, Conroy PC, Calthorpe L, Shui AM, Kitahara CM, Roman SA, Sosa JA. Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid Cancer and Distant Metastases in the United States, 1992–2018. Thyroid. 2023;33(1):63–73.CrossRefPubMedPubMedCentral
19.
go back to reference Jianyong L, Jinjing Z, Zhihui L, Tao W, Rixiang G, Jingqiang Z. A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid. 2018;28(3):301–10.CrossRefPubMed Jianyong L, Jinjing Z, Zhihui L, Tao W, Rixiang G, Jingqiang Z. A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid. 2018;28(3):301–10.CrossRefPubMed
20.
go back to reference Hutchinson KA, Guerra A, Payne AE, Turkdogan S, Forest VI, Hier MP, Payne RJ. Risk Factors Associated With Reoperative Surgery for Thyroid Malignancies: A Retrospective Cohort Study. Otolaryngol Head Neck Surg. 2023;168(3):392–7.CrossRefPubMed Hutchinson KA, Guerra A, Payne AE, Turkdogan S, Forest VI, Hier MP, Payne RJ. Risk Factors Associated With Reoperative Surgery for Thyroid Malignancies: A Retrospective Cohort Study. Otolaryngol Head Neck Surg. 2023;168(3):392–7.CrossRefPubMed
21.
go back to reference Mauri G, Hegedus L, Bandula S, Cazzato RL, Czarniecka A, Dudeck O, Fugazzola L, Netea-Maier R, Russ G, Wallin G, et al. European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J. 2021;10(3):185–97.CrossRefPubMedPubMedCentral Mauri G, Hegedus L, Bandula S, Cazzato RL, Czarniecka A, Dudeck O, Fugazzola L, Netea-Maier R, Russ G, Wallin G, et al. European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J. 2021;10(3):185–97.CrossRefPubMedPubMedCentral
22.
go back to reference Wang D, Hu J, Deng C, Yang Z, Zhu J, Su X. Predictive nomogram for central lymph node metastasis in papillary thyroid microcarcinoma based on pathological and ultrasound features. Front Endocrinol (Lausanne). 2023;14:1108125.CrossRefPubMed Wang D, Hu J, Deng C, Yang Z, Zhu J, Su X. Predictive nomogram for central lymph node metastasis in papillary thyroid microcarcinoma based on pathological and ultrasound features. Front Endocrinol (Lausanne). 2023;14:1108125.CrossRefPubMed
23.
go back to reference Wang Y, Guan Q, Xiang J. Nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma: a retrospective cohort study of 8668 patients. Int J Surg. 2018;55:98–102.CrossRefPubMed Wang Y, Guan Q, Xiang J. Nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma: a retrospective cohort study of 8668 patients. Int J Surg. 2018;55:98–102.CrossRefPubMed
24.
go back to reference Huang H, Xu S, Ni S, Wang X, Liu S. A nomogram for predicting lateral lymph node metastasis in cN0 unifocal papillary thyroid microcarcinoma. BMC Cancer. 2023;23(1):718.CrossRefPubMedPubMedCentral Huang H, Xu S, Ni S, Wang X, Liu S. A nomogram for predicting lateral lymph node metastasis in cN0 unifocal papillary thyroid microcarcinoma. BMC Cancer. 2023;23(1):718.CrossRefPubMedPubMedCentral
25.
go back to reference Tuttle RM, Zhang L, Shaha A. A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. Expert Rev Endocrinol Metab. 2018;13(2):77–85.CrossRefPubMedPubMedCentral Tuttle RM, Zhang L, Shaha A. A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. Expert Rev Endocrinol Metab. 2018;13(2):77–85.CrossRefPubMedPubMedCentral
26.
go back to reference Sun J, Jiang Q, Wang X, Liu W, Wang X. Nomogram for preoperative estimation of cervical lymph node metastasis risk in papillary thyroid microcarcinoma. Front Endocrinol (Lausanne). 2021;12:613974.CrossRefPubMed Sun J, Jiang Q, Wang X, Liu W, Wang X. Nomogram for preoperative estimation of cervical lymph node metastasis risk in papillary thyroid microcarcinoma. Front Endocrinol (Lausanne). 2021;12:613974.CrossRefPubMed
27.
go back to reference Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G, Di Paolo A, Stati V, Chiefari A, Vottari S, et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association Stratification System. Thyroid. 2020;30(5):713–9.CrossRefPubMed Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G, Di Paolo A, Stati V, Chiefari A, Vottari S, et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association Stratification System. Thyroid. 2020;30(5):713–9.CrossRefPubMed
28.
go back to reference Shobab L, Burman KD, Wartofsky L. Sex differences in differentiated thyroid cancer. Thyroid. 2022;32(3):224–35.CrossRefPubMed Shobab L, Burman KD, Wartofsky L. Sex differences in differentiated thyroid cancer. Thyroid. 2022;32(3):224–35.CrossRefPubMed
29.
go back to reference Xu L, Li G, Wei Q, El-Naggar AK, Sturgis EM. Family history of cancer and risk of sporadic differentiated thyroid carcinoma. Cancer. 2012;118(5):1228–35.CrossRefPubMed Xu L, Li G, Wei Q, El-Naggar AK, Sturgis EM. Family history of cancer and risk of sporadic differentiated thyroid carcinoma. Cancer. 2012;118(5):1228–35.CrossRefPubMed
30.
go back to reference Xu S, Huang H, Qian J, Liu Y, Huang Y, Wang X, Liu S, Xu Z, Liu J. Prevalence of hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes. JAMA Netw Open. 2021;4(7):e2118526.CrossRefPubMedPubMedCentral Xu S, Huang H, Qian J, Liu Y, Huang Y, Wang X, Liu S, Xu Z, Liu J. Prevalence of hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes. JAMA Netw Open. 2021;4(7):e2118526.CrossRefPubMedPubMedCentral
31.
go back to reference Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–501.CrossRefPubMedPubMedCentral Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–501.CrossRefPubMedPubMedCentral
32.
go back to reference Liu F, Xing L, Zhang X, Zhang X. A four-pseudogene classifier identified by machine learning serves as a novel prognostic marker for survival of osteosarcoma. Genes (Basel). 2019;10(6):414.CrossRefPubMed Liu F, Xing L, Zhang X, Zhang X. A four-pseudogene classifier identified by machine learning serves as a novel prognostic marker for survival of osteosarcoma. Genes (Basel). 2019;10(6):414.CrossRefPubMed
Metadata
Title
A nomogram for predicting adverse pathologic features in low-risk papillary thyroid microcarcinoma
Authors
Lei Gong
Ping Li
Jingjing Liu
Yan Liu
Xinghong Guo
Weili Liang
Bin Lv
Peng Su
Kai Liang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12012-3

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine